Abeona raises $25M in registered direct offering at $4.03/share to fund EB-101 launch prep

ABEONA THERAPEUTICS INC.

Gross proceeds ~$25M; net ~$22.9M after fees and expenses.
Issued 3,284,407 shares and pre-funded warrants for 2,919,140 shares at $4.03 per share.
Proceeds primarily for commercial launch preparation for gene therapy EB-101 (BLA pending).
Offering led by Nantahala Capital Management; includes Adage Capital Partners and two other institutions.
Closing expected on or about July 6, 2023, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ABEONA THERAPEUTICS INC. entered into Purchase Agreement with certain existing institutional investors valued at approximately $22.9 million (effective 2023-07-03).

Action: entry
Agreement: equity purchase
Counterparty: certain existing institutional investors
Value: approximately $22.9 million
Effective: 2023-07-03

Exact text from the filing

On July 3, 2023, Abeona Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain existing institutional investors relating to the issuance and sale of an aggregate of (a) 3,284,407 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 2,919,140 shares of the Company’s common stock (the “Pre-Funded Warrants”)

View on SEC.gov

295 material agreements filed in the last 30 days. Browse all material agreements →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-023235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.